Vaxart, Inc. (VXRT)
0.6380
-0.01
(-1.54%)
USD |
OTCM |
Mar 20, 16:00
Vaxart Research and Development Expense (Quarterly) : 45.15M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | 9.921M |
| Nuwellis, Inc. | 0.884M |
| Capricor Therapeutics, Inc. | 22.88M |
| Allogene Therapeutics, Inc. | 25.58M |
| Silvergate Capital Corp. | -- |